Cargando…
A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections Assessed in Cynomolgus Monkey Models
Recently, we successfully transplanted an autograft, or major histocompatibility complex (MHC)-matched allografts, from induced-pluripotent-stem-cell-derived retinal pigment epithelial (iPSC-RPE) cells in patients with age-related macular degeneration. However, there was an issue regarding immune re...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247695/ https://www.ncbi.nlm.nih.gov/pubmed/32349277 http://dx.doi.org/10.3390/ijms21093077 |
_version_ | 1783538212872912896 |
---|---|
author | Fujii, Shota Sugita, Sunao Futatsugi, Yoko Ishida, Masaaki Edo, Ayaka Makabe, Kenichi Kamao, Hiroyuki Iwasaki, Yuko Sakaguchi, Hirokazu Hirami, Yasuhiko Kurimoto, Yasuo Takahashi, Masayo |
author_facet | Fujii, Shota Sugita, Sunao Futatsugi, Yoko Ishida, Masaaki Edo, Ayaka Makabe, Kenichi Kamao, Hiroyuki Iwasaki, Yuko Sakaguchi, Hirokazu Hirami, Yasuhiko Kurimoto, Yasuo Takahashi, Masayo |
author_sort | Fujii, Shota |
collection | PubMed |
description | Recently, we successfully transplanted an autograft, or major histocompatibility complex (MHC)-matched allografts, from induced-pluripotent-stem-cell-derived retinal pigment epithelial (iPSC-RPE) cells in patients with age-related macular degeneration. However, there was an issue regarding immune rejection after transplantation. In this study, we established a preoperational in vitro “drug–lymphocytes–grafts immune reaction (Drug-LGIR)” test to determine the medication for immune rejection using host immunocompetent cells (lymphocytes) and transplant cells (target iPSC-RPE cells) together with different medications. The adequacy of the test was assessed by in vivo transplantation in monkey models together with medication based on in vitro data. In the results of Drug-LGIR tests, some drugs exhibited significant suppression of RPE cell-related allogeneic reactions, while other drugs did not, and the efficacy of each drug differed among the recipient monkeys. Based on the results of Drug-LGIR, we applied cyclosporine A or local steroid (triamcinolone) therapy to two monkeys, and successfully suppressed RPE-related immune rejections with RPE grafts, which survived without any signs of rejection under drug administration. We propose that our new preoperational in vitro Drug-LGIR test, which specifies the most efficacious medication for each recipient, is useful for controlling immune attacks with personalized treatment for each patient after retinal transplantation. |
format | Online Article Text |
id | pubmed-7247695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72476952020-06-10 A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections Assessed in Cynomolgus Monkey Models Fujii, Shota Sugita, Sunao Futatsugi, Yoko Ishida, Masaaki Edo, Ayaka Makabe, Kenichi Kamao, Hiroyuki Iwasaki, Yuko Sakaguchi, Hirokazu Hirami, Yasuhiko Kurimoto, Yasuo Takahashi, Masayo Int J Mol Sci Article Recently, we successfully transplanted an autograft, or major histocompatibility complex (MHC)-matched allografts, from induced-pluripotent-stem-cell-derived retinal pigment epithelial (iPSC-RPE) cells in patients with age-related macular degeneration. However, there was an issue regarding immune rejection after transplantation. In this study, we established a preoperational in vitro “drug–lymphocytes–grafts immune reaction (Drug-LGIR)” test to determine the medication for immune rejection using host immunocompetent cells (lymphocytes) and transplant cells (target iPSC-RPE cells) together with different medications. The adequacy of the test was assessed by in vivo transplantation in monkey models together with medication based on in vitro data. In the results of Drug-LGIR tests, some drugs exhibited significant suppression of RPE cell-related allogeneic reactions, while other drugs did not, and the efficacy of each drug differed among the recipient monkeys. Based on the results of Drug-LGIR, we applied cyclosporine A or local steroid (triamcinolone) therapy to two monkeys, and successfully suppressed RPE-related immune rejections with RPE grafts, which survived without any signs of rejection under drug administration. We propose that our new preoperational in vitro Drug-LGIR test, which specifies the most efficacious medication for each recipient, is useful for controlling immune attacks with personalized treatment for each patient after retinal transplantation. MDPI 2020-04-27 /pmc/articles/PMC7247695/ /pubmed/32349277 http://dx.doi.org/10.3390/ijms21093077 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fujii, Shota Sugita, Sunao Futatsugi, Yoko Ishida, Masaaki Edo, Ayaka Makabe, Kenichi Kamao, Hiroyuki Iwasaki, Yuko Sakaguchi, Hirokazu Hirami, Yasuhiko Kurimoto, Yasuo Takahashi, Masayo A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections Assessed in Cynomolgus Monkey Models |
title | A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections Assessed in Cynomolgus Monkey Models |
title_full | A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections Assessed in Cynomolgus Monkey Models |
title_fullStr | A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections Assessed in Cynomolgus Monkey Models |
title_full_unstemmed | A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections Assessed in Cynomolgus Monkey Models |
title_short | A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections Assessed in Cynomolgus Monkey Models |
title_sort | strategy for personalized treatment of ips-retinal immune rejections assessed in cynomolgus monkey models |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247695/ https://www.ncbi.nlm.nih.gov/pubmed/32349277 http://dx.doi.org/10.3390/ijms21093077 |
work_keys_str_mv | AT fujiishota astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT sugitasunao astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT futatsugiyoko astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT ishidamasaaki astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT edoayaka astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT makabekenichi astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT kamaohiroyuki astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT iwasakiyuko astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT sakaguchihirokazu astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT hiramiyasuhiko astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT kurimotoyasuo astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT takahashimasayo astrategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT fujiishota strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT sugitasunao strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT futatsugiyoko strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT ishidamasaaki strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT edoayaka strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT makabekenichi strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT kamaohiroyuki strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT iwasakiyuko strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT sakaguchihirokazu strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT hiramiyasuhiko strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT kurimotoyasuo strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels AT takahashimasayo strategyforpersonalizedtreatmentofipsretinalimmunerejectionsassessedincynomolgusmonkeymodels |